The macrophage activation syndrome market is experiencing steady growth, driven by broadened treatment options, improved survival outcomes, and the launch of emerging therapies such as targeting SIRP-α/β1/γ (ELA026), targeting Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) (Plonmarlimab), IL-18 inhibitor (Tadekinig alfa), dual IL-1β and IL-18 inhibitor (MAS825), and others.
LAS VEGAS, Jan. 13, 2026 /PRNewswire/ — DelveInsight’s Macrophage Activation Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, macrophage activation syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Macrophage Activation Syndrome Market Summary
Discover the new macrophage activation syndrome treatment @ Macrophage Activation Syndrome Treatment Market
Key Factors Driving the Growth of the Macrophage Activation Syndrome Market
Macrophage Activation Syndrome Market Analysis
Macrophage Activation Syndrome Competitive Landscape
The MAS drugs in clinical trials include ELA026 (Electra Therapeutics), Plonmarlimab (TJ Biopharma), Tadekinig alfa (AB2 Bio), MAS825 (Novartis), and others.
Electra Therapeutics’ ELA026 is a first-in-class monoclonal antibody designed to target Signal Regulatory Proteins (SIRPs) expressed on the surface of myeloid cells and T lymphocytes, enabling the selective elimination of disease-driving immune cells. This innovative mechanism offers potential therapeutic value across a broad range of conditions.
AB2 Bio’s Tadekinig alfa is a novel recombinant form of human interleukin-18 binding protein (IL-18BP) that neutralizes IL-18, a key pro-inflammatory cytokine. In healthy individuals, excess endogenous IL-18BP maintains systemic free IL-18 at undetectable levels. Tadekinig alfa is currently being evaluated in a Phase III clinical trial.
In January 2025, AB2 Bio announced an option and licensing agreement with Nippon Shinyaku covering the United States. Under this agreement, Nippon Shinyaku holds exclusive commercialization rights for Tadekinig alfa in its lead indication, primary monogenic IL-18-driven hyperinflammatory syndrome associated with NLRC4 mutations and XIAP deficiency, across the US, including Guam, Puerto Rico, and the US Virgin Islands. AB2 Bio retains rights for all other indications within these territories, as well as for all indications outside the US. AB2 Bio continues to advance preparations for submission of a US Biologics License Application (BLA) for Tadekinig alfa in this indication.
The anticipated launch of these emerging therapies are poised to transform the macrophage activation syndrome market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the macrophage activation syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the macrophage activation syndrome drugs @ Macrophage Activation Syndrome Drugs Market
Recent Developments in the Macrophage Activation Syndrome Market
What is Macrophage Activation Syndrome?
Macrophage activation syndrome (MAS) is a rare, severe, and potentially life-threatening hyperinflammatory condition characterized by uncontrolled activation and proliferation of macrophages and T lymphocytes, leading to a cytokine storm. It is most commonly associated with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease. Still, it can also occur in the context of infections, malignancies, or other autoimmune and autoinflammatory disorders. MAS results in excessive immune-mediated tissue damage and is marked by clinical features such as persistent high fever, hepatosplenomegaly, cytopenias, liver dysfunction, coagulopathy, and markedly elevated inflammatory markers, particularly ferritin. Prompt recognition and aggressive immunosuppressive treatment are critical, as MAS can rapidly progress to multi-organ failure if left untreated.
Macrophage Activation Syndrome Epidemiology Segmentation
The macrophage activation syndrome epidemiology section provides insights into the historical and current macrophage activation syndrome patient pool and forecasted trends for the leading markets. MAS spans both pediatric and adult populations, occurring most frequently in children with sJIA and KD. In contrast, adult cases are more common in AOSD, SLE, and secondary triggers such as infections or malignancies.
The macrophage activation syndrome treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
Scope of the Macrophage Activation Syndrome Market Report
Download the report to understand what is the latest research on macrophage activation syndrome @ New Macrophage Activation Syndrome Medication
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.
Adult-Onset Still’s Disease Market
Adult-Onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key AOSD companies including Novartis, Swedish Orphan Biovitrum, Roche, Cerecor, AB2 Bio Ltd, among others.
Juvenile Idiopathic Arthritis Market
Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key JIA companies including Regeneron, Sanofi, AbbVie, Eli Lilly and Company, Incyte Corporation, Johnson & Johnson, Hope Biosciences, Bristol-Myers Squibb, UCB Biopharma, Novartis, among others.
Kawasaki Disease Market
Kawasaki Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Kawasaki disease companies including Green Cross Corporation, GC Biopharma Corp, Mitsubishi Tanabe Pharma Corporation, Centocor Inc., Amgen, Takeda, The Emmes Company LLC, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
